The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation | Zendy

Takayoshi KomatsuFujii | Zendy; Yuko Chinuki | Zendy; Hiroyuki Niihara | Zendy; Kenji Hayashida | Zendy; Masataka Ohta | Zendy; Ryota Okazaki | Zendy; Sakae Kaneko | Zendy; Eishin Morita | Zendy

Open Access

The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation

Author(s) -

Takayoshi KomatsuFujii,

Yuko Chinuki,

Hiroyuki Niihara,

Kenji Hayashida,

Masataka Ohta,

Ryota Okazaki,

Sakae Kaneko,

Eishin Morita

Publication year - 2017

Publication title -

allergology international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.49

H-Index - 58

eISSN - 1440-1592

pISSN - 1323-8930

DOI - 10.1016/j.alit.2017.06.001

Subject(s) - medicine , systemic inflammation , biomarker , toxic epidermal necrolysis , immunology , inflammation , gastroenterology , dermatology , biochemistry , chemistry

In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug eruptions. The aim of this study was to test whether the thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption can serve as a prognostic biomarker of systemic inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research